结合内皮素-1 拮抗剂和 SGLT-2 抑制剂靶向内皮：两者结合效果更好？

IF 6.7 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Clinical science Pub Date : 2024-06-05 DOI:10.1042/CS20240605

Phil Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni, Jan Oscarsson, Anthony P Davenport

{"title":"结合内皮素-1 拮抗剂和 SGLT-2 抑制剂靶向内皮：两者结合效果更好？","authors":"Phil Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni, Jan Oscarsson, Anthony P Davenport","doi":"10.1042/CS20240605","DOIUrl":null,"url":null,"abstract":"Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.","PeriodicalId":10475,"journal":{"name":"Clinical science","volume":"138 11","pages":"687-697"},"PeriodicalIF":6.7000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?\",\"authors\":\"Phil Ambery, Peter J Greasley, Robert I Menzies, Lena Brynne, Spoorthy Kulkarni, Jan Oscarsson, Anthony P Davenport\",\"doi\":\"10.1042/CS20240605\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.\",\"PeriodicalId\":10475,\"journal\":{\"name\":\"Clinical science\",\"volume\":\"138 11\",\"pages\":\"687-697\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2024-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1042/CS20240605\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1042/CS20240605","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

内皮素 A 和 B 受体以及钠-葡萄糖共转运体-2（SGLT-2）通道是改善内皮功能的重要靶点，近年来使用抑制剂进行干预已成为多项机理和临床结果试验的主题。显著的成功案例包括使用内皮素受体拮抗剂治疗肺动脉高压，以及使用 SGLT-2 抑制剂治疗心力衰竭和慢性肾病。在这篇综述中，我们将探讨以内皮功能障碍为核心的多种疾病的联合治疗逻辑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?

Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical science 医学-医学：研究与实验

CiteScore

11.40

自引率

0.00%

发文量

189

审稿时长

4-8 weeks

期刊介绍： Translating molecular bioscience and experimental research into medical insights, Clinical Science offers multi-disciplinary coverage and clinical perspectives to advance human health. Its international Editorial Board is charged with selecting peer-reviewed original papers of the highest scientific merit covering the broad spectrum of biomedical specialities including, although not exclusively: Cardiovascular system Cerebrovascular system Gastrointestinal tract and liver Genomic medicine Infection and immunity Inflammation Oncology Metabolism Endocrinology and nutrition Nephrology Circulation Respiratory system Vascular biology Molecular pathology.